West Pharmaceutical (WST) stock plummeted 24.11% on Thursday morning's pre-market session, following the company's weaker-than-expected guidance for 2025 due to factors like biotech customers reducing pandemic-era inventories and headwinds from a strong U.S. dollar.
The medical equipment maker forecast 2025 adjusted earnings per share of $6 to $6.20, well below analysts' average estimate of $7.44. It also projected full-year revenue between $2.88 billion and $2.91 billion, missing expectations of $3.04 billion.
West Pharma cited the ongoing impact of destocking by its biotech clients, who had built up inventories during pandemic supply chain disruptions. The company's CEO Eric Green noted that "the impact of destocking continues to moderate" but remains a challenge. A strong U.S. dollar also weighed on the outlook by impacting overseas revenues.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。